Latest News !
 

Federal Budget 2019 - Comment & Analysis

Dr Boreham's Crucible: Osprey Medical

2018 - The Year In Review

Bionomics Falls 69% As BNC210 Fails PTSD Primaary Endpoints

Neuren, Acadia $630m North America Trofinetide Licence

Benitec Up 124% On Up-To $892m Axovant Gene Therapy Deal

Prana Back In The Clinic With PBT434 For Parkinson's Disease

March BDI-40 Up 6%, ASX200 Up 0.2%
Big Caps Flat, NBI Down 0.1%

 Avita Up 107%, Paradigm 66%, Uscom 47%; Oncosil Down 78%, Cynata 22%

April 1, 2019

March was good for Australian biotechnology, with Avita and Paradigm breaking out to their highest market capitalizations in their history.

The Biotech Daily Top 40 Index (BDI-40) climbed 5.9 percent out-performing the ASX200 up 0.2 percent, while the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) slipped a collective 0.02 percent and the Nasdaq Biotechnology Index (NBI) was down 0.1 cents.

 

For the year to March 31, 2019, the BDI-40 was up 1.0 percent, the ASX200 rose 7.3 percent, the Big Caps improved 20.05 percent and the NBI was up 4.7 percent.

 

In March, 19 of the Biotech Daily Top 40 Index (BDI-40) stocks were up, 13 by more than 10 percent, 16 fell, with seven losing more than 10 percent, and five were unchanged.

 

Avita was the best, up 107.1 percent for the month and 784.7 percent for the year to $522 million, followed by Paradigm up 65.8 percent for the month and 662.9 percent for the year to $267 million. Uscom was up 47.1 percent in March, followed by Compumedics (37.9%), Osprey (30.2%), Genetic Signatures (23.2%), Medical Developments (18.3%), Telix (17.3%), Volpara (16.1%), Antisense (14.3%), LBT (14.3%), Prana (13.6%) and Mesoblast (12.2%).

 

Oncosil led the falls on bad CE mark news, down $89 million or 78.1 percent to $25 million, followed by Cynata (22.4%), Prescient (14.3%), Impedimed (13.7%), Optiscan (13.6%), Universal Biosensors (12.5%) and Kazia (12.1%).

 

In March, Cochlear improved 1.2 percent to $9,959 million, CSL slipped 0.06 percent to $87,719 million and Resmed shed 0.4 percent to $20,704 million.

 

Outside the Top 40, Resonance continued its record run, up 19.4 percent for the month and 362.5 percent for the year to $37 million, Alcidion was up 71.9 percent for the month and 129.2 percent for the year to $55 million, Bluechiip was up 95.8 percent for the year to $47 million, with Elixinol Global up 222.9 percent for the year to $565 million and it hasn’t really become a medical marijuana company, yet. Medadvisor and Recce were also up.

 

Nine of the 16 stocks in Cannabis Corner fell, four were up and three were unchanged, with Cann Group up 31.6 percent and Elixinol up 32.0 percent.

 

On the Nasdaq, Queensland’s Protagonist was up 45.3 percent to $414 million; from a low base, Vaxart (Biota) was up 35.2 percent to $23 million; Israel’s Redhill (with Australian assets) was up 8.5 percent to $332 million; and Eyepoint (Psivida) fell 30.5 percent to $241 million.

 

BDI-40 v S&P ASX200 Jun 30, 2006 to Mar 31, 2019 

 

Big Caps (Cochlear, CSL, Resmed) Mar 31, 2016 To Mar 31, 2019